Keshav Rajul Gandhi

Mr. Keshav Rajul Gandhi


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2025 in Vaccine
Verified
Journal Article
Open access
KGKeshav Rajul Gandhi
Keshav Rajul Gandhi
YVYash Vijay
Yash Vijay
KPKimberly Page
Kimberly Page
HDHarel Dahari
Harel Dahari
AGAlexander Gutfraind
Alexander Gutfraind
Motivated by the high mortality burden of hepatitis C virus (HCV) and the unprecedented rapid development of the COVID-19 and respiratory syncytial virus (RSV) vaccines, we note that a prompt HCV vaccine rollout may streamline the World Health Organization's goal to eliminate HCV before 2030. While progress in the development of HCV vaccine candidates has rapidly flourished, vaccine hesitancy and HCV incidence are both particularly prevalent in people who inject drugs (PWID). The aim of this paper is to document several potential challenges in HCV vaccine uptake and provide a set of preliminary recommendations for public and community health professionals to improve acceptance. We conducted a forward-looking integrative narrative review and identified relevant articles from PubMed. We survey literature discussing barriers to vaccine acceptance in past rollouts (e.g., COVID-19, hepatitis B) and barriers to HCV management, particularly in PWID. Six key challenges were identified: (1) structural and social barriers affecting PWID, (2) vaccine safety, efficacy, and relevance concerns, (3) multiple-dose attrition and vaccine fatigue, (4) media presentation and misinformation, (5) awareness and attitude towards infection, and (6) information framing and primary care linkage. Four possible recommendations were also identified: (1) vaccine promotion in targeted educational and outreach campaigns, (2) community-level support programs integrated with vaccine rollout, (3) rollout of a pan-genotypic, multivalent, or combination vaccine, and (4) cost-benefit analysis supporting the vaccine. This forward-looking paper offers several recommendations to address potential gaps in HCV vaccination-from linkage with syringe exchange programs to economic analysis of vaccination program costs.

31 January 2025 in medRxiv
Verified
Preprint
Open access
PDF file
KGKeshav Rajul Gandhi
Keshav Rajul Gandhi
SASami Alahmadi
Sami Alahmadi
RHRosie Hanneke
Rosie Hanneke
AGAlexander Gutfraind
Alexander Gutfraind
Introduction Motivated by the disproportionate burden of infectious diseases on vulnerable populations and the risk of future pandemics, we conducted a scoping review to analyze the state of the literature about “vaccine uptake indices,” defined as models that predict vaccination rates by geospatial area. We analyzed novel vaccine uptake indices created in response to the recent COVID-19 pandemic. The aim of this scoping review is to survey the state of the literature regarding vaccine uptake indices relating to COVID-19 and other infectious diseases. Methods We conducted a scoping review with a systematic search strategy to identify relevant articles from the databases Embase, PubMed, and Web of Science with title and abstract screening, full-text review, and data extraction. Results Database searches resulted in 3,615 potential articles, of which 229 reports were included. Fifteen studies (7%) were determined to be methodologically advanced vaccine uptake indices that had at least three of the following characteristics: the use of individual- and population-level predictor variables (100 [44%]), geo-spatiotemporal analysis (58 [25%]), data usage agnostic to vaccine specificity (50 [22%]), or sociobehavioral frameworks of health (such as the Health Belief Model and Theory of Planned Behavior) (30 [13%]). Conclusion This scoping review offers suggestions for future research of next-generation vaccine uptake indices before use in vaccination campaigns of recurring or novel infectious diseases. Areas to pursue include utilizing individual-level data about vaccination behaviors in conjunction with administrative data, solving the challenge of implementing small-area spatiotemporal analysis, using vaccine-agnostic methods that consider data from more than one infectious disease, and assisting causal inference with theoretical frameworks.

20 November 2026 in medRxiv
Verified
Preprint
Open access
KGKeshav Rajul Gandhi
Keshav Rajul Gandhi
SMSophia Mao
Sophia Mao
ETEric Tatara
Eric Tatara
JJonathan Ozik
Jonathan Ozik
BBBasmattee Boodram
Basmattee Boodram
HDHarel Dahari
Harel Dahari
Background and Aims: The probability of hepatitis C virus (HCV) clearance is mediated by an interaction between numerous factors. However, variation in spontaneous HCV clearance was previously modeled using relatively simple approaches with fixed probabilities by sex. Here, we developed a literature-informed clearance algorithm that considers age, sex, interferon lambda 4 (IFNL4) genotype, and infection history to model the probability of HCV clearance in vulnerable populations, such as people who inject drugs (PWID), and in controlled human infection (CHI) models for future HCV vaccines. Methods: We modeled HCV clearance probabilities for three infection-history pathways: first infection, reinfection after spontaneous clearance, and reinfection after direct-acting antiviral (DAA) cure. Logistic and cumulative-hazard equations assigned person-specific clearance probabilities in the first two pathways. The post-DAA pathway used fixed clearance probabilities. We tested the algorithm using HepCEP (Hepatitis C Elimination in PWID), an agent-based simulator. Results: First-infection clearance probabilities ranged from 0.13 to 0.51 across eight age, sex, and IFNL4 genotype subgroups. Clearance probabilities for reinfection after spontaneous clearance ranged from 0.20 to 0.80 at literature point estimates. Across 100 runs, the mean assigned clearance probabilities were 0.27 for first infections and 0.52 for reinfections after spontaneous clearance, compared with literature inputs of 0.26 and 0.52, respectively. Probabilities varied across subgroups and runs. Conclusion: Simulations reproduced the algorithm's intended clearance heterogeneity and uncertainty by age, sex, IFNL4 genotype, and infection history, which may support models of HCV elimination in vulnerable populations and CHI model development for future HCV vaccines.

4 May 2026 in Journal of Open Source Software
Verified
Journal Article
Open access
PDF file
JAJoshua M. Allen
Joshua M. Allen
KGKeshav Rajul Gandhi
Keshav Rajul Gandhi
RARaghid Alhazmy
Raghid Alhazmy
YWYash Wasnik
Yash Wasnik
CFChristina E. Fliege
Christina E. Fliege